CoChat

xCT inhibition sensitizes tumors to γ-radiation via glutathione reduction

Open access
Cobler, Lara, Zhang, Hui, Suri, Poojan, Park, Catherine, Timmerman, Luika A. · 2018 · Oncotarget
Cited by 71

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Abstract

// Lara Cobler 1 , Hui Zhang 1, 2 , Poojan Suri 3 , Catherine Park 1, 2 and Luika A. Timmerman 1 1 Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA 2 Department of Radiation Oncology, University of California, San Francisco, CA, USA 3 University of California, San Francisco, CA, USA Correspondence to: Luika A. Timmerman, email: Luika.Timmerman@ucsf.edu Keywords: radiation sensitize; glutathione; xCT; SLC7A11; radiation therapy Received: June 26, 2018 Accepted: July 08, 2018 Published: August 17, 2018 ABSTRACT About 3 million US cancer patients and 1.7 million EU cancer patients received multiple doses of radiation therapy (RT) in 2012, with treatment duration limited by normal adjacent tissue damage. Tumor-specific sensitization could allow treatment with lower radiation doses, reducing normal tissue damage. This is a longstanding, largely unrealized therapeutic goal. The cystine:glutamate exchanger xCT is expressed on poor prognosis subsets of most solid tumors, but not on most normal cells. xCT provides cells with environmental cystine for enhanced glutathione synthesis. Glutathione is used to control reactive oxygen species (ROS), which are therapeutic effectors of RT. We tested whether xCT inhibition would sensitize xCT + tumor cells to ionizing radiation. We found that pretreatment with the xCT inhibitor erastin potently sensitized xCT + but not xCT - cells, in vitro and in xenograft. Similarly, targeted gene inactivation also sensitized cells, and both modes of sensitization were overcome by glutathione supplementation. Sensitization prolongs DNA damage signaling, increases genome instability, and enhances cell death, revealing an unforeseen role for cysteine in genome integrity maintenance. We conclude that an xCT-specific therapeutic would provide tumor-specific sensitization to RT, allowing treatment with lower radiation doses, and producing far fewer side effects than other proposed sensitizers. Our data speaks to the need for the rapid development of such a drug.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.25794

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Cited by

Metadata

Authors
Cobler, L., Zhang, H., Suri, P., Park, C., & Timmerman, L. A.
Venue
Oncotarget
Published
2018-08-17
Volume
9
Issue
64
Pages
32280-32297
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2887290711
Cited by
71
References
18
FWCI
2.44
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.